B. Riley analyst Neil Chatterji lowered the firm’s price target on OptimizeRx to $28 from $30 and keeps a Buy rating on the shares post the Q4 results. The analyst took down 2023 revenue estimates post the "slight miss" but views the post-earnings selloff as a buying opportunity. The firm sees an opportunity to accumulate more shares as broader macro-related headwinds subside and digital pharma spend increases,.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx Announces Multi-Year Agreement with Top Hub Services Provider to Accelerate Access for Patients
- OptimizeRx sees FY23 revenue up at least 10%, consensus $77.8M
- OptimizeRx sees Q1 revenue $11.5M-$13M, consensus $16.15M
- OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results
- OptimizeRx reports Q4 EPS 25c, consensus 24c
